infectious disease

To be clear, any adverse event is always one too many. But in the real world, these things happen and often through no intrinsic fault of the therapeutic intervention

Oral ibrexafungerp shows positive results in Phase 3 study against difficult fungal infections

Dealing with viruses, bacteria and other pathogens requires many approaches

Wide adoption and regimen compliance are two reasons for easier administration, whether with COVID or schizophrenia

This webinar will examine ways that scientists discover and use monoclonal antibodies for the treatment of infectious diseases and discuss exciting developments in monoclonal antibody research.

A look at our new online venue for infectious diseases as well as upcoming coverage

Injectable cabotegravir outperforms oral standard of care for preventing HIV in women